Pharmaceutical giant GlaxoSmithKline revealed more bad news Wednesday, disclosing that Beijing officials have barred GSK's head of finance for China from leaving the country amid accusations of widening $490 million bribery scandal.
GSK's China finance director Steve Nechelput's foreign travel has been restricted since late June, according the British drug company, which pointed out he is still working and allowed to travel within China.
"It is important to stress that at no time has he been questioned or arrested—nor is he one of the individuals in detention," said a GSK spokesman of the British national Nechelput.
That's small comfort to GSK, which has seen four of its Chinese executives detained because of the alleged bribery scandal, which comes on the heels of the company firing its head of research in development in China over a published article that misrepresented data.
After GSK fired its R&D boss, the company said in June that it had investigated allegations made by an anonymous tipster that GSK employees engaged in bribery and corruption to influence doctors in China to prescribe drugs for years. The company said a four-month probe found no evidence of wrongdoing.
But within weeks, Chinese police accused Glaxo of funneling almost $490 million to 700 travel agencies and other businesses over the years to dole out bribes to officials and doctors in the country.
(Read more: GSK fires China R&D boss)